The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.

Leo ThomasEric MartelWolfgang RistIngo UphuesDieter HamprechtHeike NeubauerRobert Augustin

Published in: Diabetes, obesity & metabolism (2024)

Survodutide was selected as the clinical candidate based on its balanced dual GCGR/GLP-1R pharmacology, engaging the GCGR for robust body weight-lowering efficacy exceeding that of selective GLP-1R agonists, while achieving antidiabetic efficacy that was comparable to selective GLP-1R agonism. Survodutide is currently being investigated in Phase 3 clinical trials in people living with obesity.

Keyphrases

body weight
clinical trial
type diabetes
metabolic syndrome
insulin resistance
weight loss
randomized controlled trial
single cell
adipose tissue
body mass index
physical activity
high resolution
skeletal muscle
atomic force microscopy
mass spectrometry
phase ii